Key takeaways
Raloxifene (Evista) and zoledronic acid (Reclast) are both used to treat osteoporosis in women, but they work in different ways and have different forms of administration. Raloxifene is a selective estrogen receptor modulator (SERM) taken as a daily oral tablet, while zoledronic acid is a bisphosphonate given as an intravenous (IV) infusion, typically once a year or every two years. Zoledronic acid can also be given as a one-time dose only. Raloxifene also helps lower the risk of invasive breast cancer in postmenopausal women, whereas zoledronic acid can be used to treat additional conditions like Paget's disease and osteoporosis in men. Common side effects of raloxifene include hot flashes and joint pain, while zoledronic acid can cause fever, muscle pain, and flu-like symptoms after infusion. Raloxifene carries a risk of blood clots and stroke, whereas zoledronic acid has risks like jawbone breakdown and kidney damage. Zoledronic acid and raloxifene are available in both brand and generic forms.
